Union Kang Bio-Tech Group (00690.HK): Signed a strategic cooperation agreement with Sinovac Biotech to expand the global market for Bogutai.

Zh tng cijng APP xn, lin kng shngw kj jtun (00690.HK) fb gnggo, q qunz zgngs bijng bkngjin j yun kjn kj yuxin gngs (bijng bkngjin) y k xng shngw zhyo gfn yuxin gngs (k xng zhyo) qindng zhnl hzu xiy, shuy k xng zhyo zi sht lb, ij, mlu g, gln bly, gn tn j mxg li g guji (hzu qy) dji shngyhu jtun chungxn gzh shsng zhliao yow b g ti de qunl. Zhtng Caijing APP News, Liankang Biological Technology Group (00690.HK) announced that its wholly-owned subsidiary, Beijing Bokang Health Gene Technology Co., Ltd. (Beijing Bokang Health), has signed a strategic cooperation agreement with Kexing Biopharmaceutical Co., Ltd. (Kexing Biopharmaceutical), granting Kexing Biopharmaceutical the exclusive rights to commercialize the innovative osteoporosis treatment drug Bogutai in six countries in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico (cooperation region).